H.C. Wainwright

On September 30, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced Phase 2 results for rinucumab, with the drug not meeting the primary endpoint of the study. On December 12, Ophthotech Corp (NASDAQ: OPHT) announced Phase 3 results for Fovista, which also did not achieve the primary...

H.C. Wainwright reiterated its Buy rating on Kite Pharma Inc (NASDAQ: KITE) on expectations that its cancer drug KTE-C19 would be approved in 2017 given more granular data on hand. “Given that KTE-C19 has demonstrated positive results in DLBCL (including relapsed and refractory subgroups),...

At a time when Nivalis Therapeutics Inc (NASDAQ: NVLS) is being thrashed with multiple downgrades, H.C. Wainwright maintains its Buy rating, despite the announcement of a trial miss. Trial Miss And Share Reaction Shares of Nivalis plunged to a new 52-week low of $2.58 after it reported that the...

H.C. Wainwright said it is not surprised by Eli Lilly and Co (NYSE: LLY)’s announcement of solanezumab failing to slow the cognitive decline in Alzheimer’s Disease patients. The news is also said to be a negative for Biogen Inc (NASDAQ: BIIB), which is testing its own Alzheimer's...

H.C. Wainwright & Co. downgraded shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) from Buy to a Neutral rating citing that fundamentals are not holding up. The firm also slashed its target price from $155 to $85 on the stock implying about 5 percent upside potentials from the...

H.C. Wainwright maintains Buy rating on TG Therapeutics Inc (NASDAQ: TGTX) as it welcomes the company’s amendment of a cancer study called GENUINE. Under GENUINE, TG is studying Ublituximab in combination with Ibrutinib versus Ibrutinib alone in patients with previously treated high-risk...

Shares of Lipocine Inc (NASDAQ: LPCN), a specialty pharmaceutical company that focuses on developing products in the are of men's and women's health, has seen its stock rise nearly 40 percent over the past two weeks. September 26: Positive Top-Line Results The company announced...

H.C. Wainwright has started coverage of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) with a Buy rating and $26 price target on potential upside from telotristat in carcinoid syndrome and sotagliflozin for type 1 diabetes. "We would be buyers of LXRX going into the December readout of the second...

H.C. Wainwright’s Corey Davis believes that what differentiates Lipocine Inc (NASDAQ: LPCN) from its competitors is the company’s oral drug delivery technology, called “Lip’ral”. Davis initiated coverage of the company with a Buy rating and price target of $25....

Inovio Pharmaceuticals Inc (NASDAQ: INO) has initiated a second clinical trial for GLS-5700, its preventive Zika vaccine, in Puerto Rico, where the infections due to the Zika virus have been declared a public health emergency. H.C. Wainwright’s Raghuram Selvaraju reiterated a Buy rating...

Galenica AG has announced a definitive agreement to acquire Relypsa Inc (NASDAQ: RLYP) for $32 per share in cash. H.C. Wainwright’s Ed Arce commented that this puts an end to “at least nine months of near constant take out speculation.” He downgraded the rating on the company...